Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Crucially, Humira costs the NHS more than £500 million a year, a sum that NHS England wants to see fall through biosimilar use. Sandoz is one such company that hopes to offer the NHS savings ...

Objectives We present a series of QAs for Humira® (adalimumab) from >500 drug substance batches produced from 4 facilities and 5 production scales from 2001-2013. Humira is approved for 10 indications ...